Glucose metabolism modulator

The term 'Glucose metabolism modulator' describes a broad functional category of pharmacological agents and physiological factors rather than a single, specific molecular target like a protein or receptor. These modulators act across various tissues—primarily the liver, skeletal muscle, adipose tissue, and pancreas—to maintain blood glucose levels within a narrow physiological range, a process known as glucose homeostasis (StatPearls, 'Physiology, Glucose Metabolism', 2023). In a therapeutic context, this category encompasses several distinct classes of drugs that target specific proteins, such as the Insulin receptor, Dipeptidyl peptidase-4 (DPP-4), Sodium-glucose co-transporter 2 (SGLT2), and Glucagon-like peptide-1 receptor (GLP-1R) (NIH, 'Insulin Resistance and Prediabetes', 2022). These drugs are central to the management of metabolic disorders, particularly Type 2 Diabetes Mellitus, where they work to improve insulin sensitivity, stimulate insulin secretion, or facilitate glucose excretion (Mayo Clinic, 'Type 2 diabetes - Diagnosis and treatment', 2023). Because the term refers to a physiological outcome or a therapeutic class involving multiple disparate targets, it is not considered a unique canonical target name in biological databases such as UniProt or IUPHAR.

Other names

Antidiabetic agentGlycemic control agentMetabolic modulatorHypoglycemic agent

Activation of the insulin receptor signaling pathway, inhibition of hepatic gluconeogenesis, inhibition of the DPP-4 enzyme to increase incretin levels, inhibition of renal glucose reabsorption via SGLT2, and agonism of the GLP-1 receptor to enhance glucose-dependent insulin secretion.